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Research Article
Implementation of at-line capillary zone
electrophoresis for fast and reliable
determination of adenovirus concentrations
in vaccine manufacturing
A CZE method was validated and implemented for fast and accurate in-process deter-
mination of adenovirus concentrations of downstream process samples obtained during
manufacturing of adenovirus vector-based vaccines. An analytical-quality-by-design ap-
proach was embraced for method development, method implementation, and method
maintenance. CZE provided separation of adenovirus particles from sample matrix com-
ponents, such as cell debris, residual DNA and proteins. The intermediate precision of the
virus particle concentration was 6.9% RSD and the relative bias was 2.3%. In comparison,
the CZE method is intended to replace a quantitative polymerase chain reaction method
which requires three replicates in three analytical runs to achieve an intermediate precision
of 8.1% RSD. Given that, in addition, the time from sampling till reporting results of the
CZE method was less than 2 h, whereas quantitative polymerase chain reaction requires
3 days, it follows that the CZE method enables faster processing times in downstream
processing.
Keywords:
Analytical quality by design / At-line IPC testing / Capillary zone electrophoresis
lifecycle management / Virus quantification DOI 10.1002/elps.201900068
1 Introduction
Modified adenoviruses are being developed as gene-delivery
vectors in vaccines against infectious diseases [1–3]. The vi-
ral DNA can be altered to render the virus non-replicating
and to encode for the vaccine’s antigen of interest, for exam-
ple, against human immunodeficiency virus or Ebola [4, 5].
Upon vaccination, the antigen will be expressed in the human
cells and presumably trigger an immune response which will
subsequently confer protection against the infectious disease.
The adenovirus vectors made by the AdVac R© technology were
modified such that they can not replicate in human cells but
can be replicated to high titers using the modified PER.C6 R©
human cell line [4, 5]. Downstream processing (DSP) for re-
covery and purification of adenovirus is described in ref. 6.
In short, the DSP process comprises cell lysis, clarification
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and filtration, purification by anion exchange chromatogra-
phy, and a buffer exchange step [7]. The purification steps
aim to remove host cell DNA, non-encapsidated viral DNA,
host cell proteins and viral proteins, and to achieve a high
concentration of adenovirus [6, 7]. The virus particle con-
centration of an adenovirus vector-based vaccine product is
an important quality attribute that should be monitored and
controlled throughout the production process [7,8]. The con-
centration of virus particles is often used to optimize and
adapt DSP. In-process control (IPC) testing of the virus con-
tent is performed during manufacturing, in order to select
DSP settings for subsequent most efficient purification [8,9].
The virus particle concentration is an essential parameter to
determine or adjust the virus load prior to anion exchange
chromatography, to adjust the salt concentration prior to
buffer exchange, and to dilute the final product to the target
concentration [7].
The concentration of adenovirus particles in vaccine pro-
cess intermediates can be determined using anion exchange
(AEX) HPLC [10–12], quantitative polymerase chain reaction
(qPCR) [13], or CZE [14, 15]. AEX-HPLC is relatively fast,
but the method suffers from serious matrix effects when the
test samples contain high salt concentrations or cell debris.
∗These authors contributed equally to the article.
Color online: See the article online to view Figs. 1–6 in color.
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Therefore, qPCR and CZE are the current methods of choice
for the quantitative analysis of adenovirus in process inter-
mediates [7, 13–15].
The analytical method for IPC testing of the virus content
ideally should meet the following requirements: 1) accurate
and precise, 2) compatible with the complex matrices of pro-
cess intermediate samples, and 3) the time-to-result (i.e., the
time between sampling and reporting of the analytical re-
sult) should be as short as possible. Imprecise or inaccurate
measurement of the virus content could lead to, for example,
overloading of the AEX column or an incorrect dilution of
the final product [7]. As the production process is typically
on-hold during an IPC test, long analysis times could lead to
product degradation during this hold. Our research focused
on an at-line testing approach which allows the adenovirus
concentration of an IPC sample to be analyzed and reported
within 4 h. For this, we implemented a CZE method provid-
ing fast determination of the virus particle concentration in
DSP intermediates. The CZE method was aimed to replace
a standard qPCR method, which takes at least one day to
achieve a reliable result for one sample. In order to replace
the qPCR method for IPC testing by CZE, equivalence be-
tween the CZE and qPCR methods was assessed by statistical
methods.
An analytical-quality-by-design (AQbD) approach was
embraced for the development, validation, and implemen-
tation of the CZE method. AQbD consists of six defined
steps [16,17]: 1) definition of the analytical target profile (ATP)
describing the objective of the test and the requirements, 2)
technology selection, 3) definition of the critical method pa-
rameters by a criticality (risk) assessment, 4) method develop-
ment by design of experiments (DOE), 5) method validation,
and 6) method maintenance. Upon completion of the first
five steps, a previously validated CZE method was proposed
as an alternative to qPCR for the quantification of intact ade-
novirus particles in samples from upstream processing and
DSP [14]. The ATP described an intermediate precision of
10% RSD of the adenovirus particle concentration for the
IPC control, a bias of 10%, and a time-to-result of less than
4 h. This paper describes the last step of the AQbD process
for the CZE method: the method maintenance. In this phase,
the method is installed (i.e., transferred to the executing lab
and implemented for routine use) and a control strategy is
defined for the critical method parameters, to assure method
performance according to requirements during routine use
of the method.
2 Materials and methods
2.1 Chemicals and materials
Tricine (PN 93356) was obtained from Sigma Aldrich (Zwijn-
drecht, the Netherlands), tris(hydroxymethyl)aminomethane
(PN 1083861000), polysorbate-20 (PN 655204), and
benzonase (PN 1.01697) were from Merck Millipore
(Amsterdam-Zuidoost, the Netherlands). Extended light path
PVA capillaries (PN G1600-61239) of 50 µm id with a
total length of 64.5 cm were from Agilent Technologies
(Waldbronn, Germany). Formulation buffer, 1 M mag-
nesium(II) chloride solution, and adenovirus crude har-
vest, lysed harvest, clarified harvest, anion-exchange prod-
uct, diafiltration product, drug substance, drug product,
and reference material (i.e., calibrant) were from Janssen
Vaccines and Prevention BV (Leiden, the Netherlands). For-
ward primer (CMV, MGB) 5′-TGGGCGGTAGGCGTGTA-
3′ (PN 4304972), reverse primer (CMV, MGB) 5′-
CGATCTGACGGTTCACTAAACG-3′ (PN 4304972), and
probe (CMV-2, MGB) 5′-VIC-TGGGAGGTCTATATAAGC-
MGB-NFQ-3 (PN 4316032) were obtained from Applied
Biosystems (Gent, Belgium).
2.2 Instrumentation and CZE method
All CZE experiments were performed on an Agilent 7100 Cap-
illary Electrophoresis system comprising a UV-Visible DAD
(Waldbronn, Germany). Data processing was performed with
Chemstation software (B.04.03). Extended light path PVA-
coated capillaries of 50 µm id (375 µm od) were cut to a
total length of 33 cm. Capillary preconditioning was per-
formed prior to each run with 10 mM phosphoric acid
and BGE at 2.5 bar for 1 min each. The BGE consisted of
125 mM Tris, 338 mM tricine (pH 7.7), and 0.2% polysorbate-
20. Sample injection was at 50 mbar for 5 s at the short
end of the capillary (8.5 cm effective length). The separa-
tion voltage was −25 kV and the capillary was thermostated
at 15°C. UV-absorbance detection was at 214 nm (4 nm
bandwidth).
Prior to every CZE run a system suitability test (SST) is
performed (see below, Section 3.3). The SST starts by fill-
ing the capillary with BGE and applying a voltage of −25 kV
without performing an injection. This step is performed to
check if the capillary is freely accessible for BGE and proper
BGE should provide a current between 40 and 60 µA. Subse-
quently, two blanks (i.e., formulation buffer) are analyzed to
check for system contamination. Next, an adenovirus system
suitability control sample with a concentration of 1.0 × 1011
adenovirus particles per mL (vp/mL) is injected six times to
check for peak area repeatability, migration time repeatabil-
ity, and concentration. The adenovirus concentration of the
control sample should be within 0.85 and 1.15 × 1011 vp/mL,
which is based on the total error (15% for 1.0 × 1011 vp/mL)
of the CZE method. All these requirements need to be met to
pass the SST. Adenovirus samples were diluted with formu-
lation buffer, if needed, to fall within the validated range of
0.5 × 1011–7.3 × 1011 vp/mL. The adenovirus concentration
of the samples was determined by one-point calibration at
7.3 × 1011 vp/mL with an adenovirus reference material (i.e.,
calibrant).
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Table 1. Overview of the between-run, within-run (method
repeatability) and total variance (intermediate
precision), the intermediate precision per testing
format, and the bias of CZE and qPCR analysis of a
clarified harvest sample (IPC)




Within-run (method repeatability) 7.4E-04 1.6E-03
Total (intermediate precision) 8.8E-04 4.7E-03
B) Intermediate precision per testing format in %RSD
Technique
Testing format CZE qPCR
One measurement in one analytical run (n = 1) 6.9 15.9
Three measurements in one analytical run (n = 3) 4.6 14.0
One measurement in three analytical runs (n = 3) 4.0 9.2
Three measurements in three analytical runs (n = 9) 2.6 8.1
C) Bias per test method
Technique
Bias CZE qPCR
Bias (log10 vp/mL) 1.0E-02 6.0E-02
Relative bias (%) 2.3 13.9
A) Between-run variance, within-run variance, and total variance
in log10 vp/mL of the CZE and qPCR methods for the
determination of the adenovirus particle concentration. B)
Intermediate precision in %RSD for different testing formats
using CZE and qPCR. C) Bias (log10 vp/mL) and relative bias (%)
of the CZE and qPCR method for adenovirus particle
concentration.
2.3 Method validation and determination of the
testing format
The method repeatability (variation within a run), intermedi-
ate precision (sum of the variation within a run and the vari-
ation between runs), and the bias were determined for CZE
and qPCR at five concentration levels in the range of 0.25
× 1011–2.0 × 1011 vp/mL, with three measurements at each
concentration level, repeated on three different days by two
different operators (Table 1). Known amounts of adenovirus
calibrant were spiked into the clarified harvest sample matrix
at levels in the range of 0.25 × 1011–2.0 × 1011 vp/mL. The in-
termediate precision acceptance criterion was 10% RSD for
the adenovirus concentration. The bias acceptance criterion
was 10% relative bias (difference between the measured
concentration and the expected reference concentration).
The intermediate precision depends on the number of
measurements and on the number of analytical runs, accord-







where Var B represents the variance between runs (variance
of the day and operator combined), Var W represents the
variance within runs, p is the number of runs, and n is the
number of measurements.
2.4 Equivalence study
Table 2 gives an overview of the process intermediates and
final product tested in the equivalence study. Three measure-
ments per sample in one analytical run (3 × 1 testing format)
were performed by qPCR and one measurement per sample
in one analytical run (1 × 1 testing format) was performed
by CZE. The qPCR analyses were performed according to
Ma et al. [13], with specific primers and probe as described
above. The CZE analyses were performed according to van
Tricht et al. [14]. The crude harvest and lysed harvest samples
were treated with benzonase (0.2 units benzonase per mL in
31 mM MgCl2 and incubated for 1 h at room temperature).
Correlated bivariate least squares (CBLS) regression [18]
was used to demonstrate the equivalence of the CZE and
qPCR method. CBLS is a regression model that takes as
dependent variable the differences between two measure-
ments of the same sample performed with both methods,
and as predictor the mean of the measurements. Then the
95% prediction interval of the differences in virus particle
concentration between qPCR and CZE are calculated for the
entire concentration range. The prediction interval is the in-
terval in which 95% of the future observations will fall. The
CZE and qPCR methods were considered equivalent or inter-
changeable in practice if the prediction interval calculated for
the differences in virus particle concentration fell within the
equivalence limits of [−0.2 to 0.2] log10 vp/mL for the entire
concentration range (i.e., the difference in concentration be-
tween CZE and qPCR for future measurements is maximally
0.2 log10 vp/mL). The BivRegBLS package in the R v.3.5.1
statistical software was used for the analyses.
3 Results and discussion
A typical result of CZE analysis of a clarified harvest IPC
sample is shown in 1. The adenovirus at 2.2 min is base-
line separated from sample matrix components, such as cell
debris, residual DNA, and proteins. The paragraphs below
describe the implementation of the CZE method, the deter-
mination of the testing format, the equivalence between CZE
and qPCR, the reduction by of the time-to-result, and the
method performance of the CZE method in routine use (over
500 runs).
3.1 Establishing the testing format based on
method validation data
Currently, qPCR is the standard method for the determina-
tion of the concentration of virus particles in IPC samples
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Table 2. Overview of process intermediates and the final product analyzed by qPCR and CZE, including number of sample lots tested,
the mean virus particle concentration, and the SD per process intermediate and final product and per method
Process intermediates and final product # lots CZE qPCR
Mean SD Mean SD
(log10 vp/mL) (log10 vp/mL) (log10 vp/mL) (log10 vp/mL)
1 - Crude harvest 13 11.14 0.12 11.16 0.10
2 - Lysed harvest 38 11.91 0.16 11.84 0.14
3 - Clarified harvest 8 11.66 0.16 11.68 0.16
4 - Anion exchange product 13 12.04 0.12 12.00 0.16
5 - Diafiltration product 9 11.77 0.13 11.79 0.15
6 - Drug substance 35 11.36 0.23 11.39 0.21
7 - Drug product 15 10.95 0.05 10.95 0.06
Figure 1. Electropherograms of a clarified harvest IPC sample
(1.3 × 1011 vp/mL) (a), a blank formulation buffer (b), an aden-
ovirus system suitability control sample (1 × 1011 vp/mL), six re-
peated analyses (overlaid) (c), and an adenovirus calibrant/assay
control (7.3 × 1011 vp/mL) (d). Conditions: BGE: 125 mM Tris and
338 mM tricine (pH 7.7) with 0.2% polysorbate-20; PVA-coated
capillary with effective length of 8.5 cm; applied voltage, −25 kV.
Other conditions: see Materials and Methods.
from the clarified harvest. Fig. 2 gives an overview of the
DSP. The adenovirus concentration determined in the IPC
sample (2) serves two purposes. Firstly, the concentration is
needed to determine the number of purification cycles for
AEX chromatography (Fig. 2d and e). If the virus particle
concentration is underestimated, for example, due to method
bias or lack of precision of the reported value, then the AEX
column might be overloaded and/or clogged. Secondly, the
determined virus concentration is used to dilute the diafiltra-
tion product (Fig. 2f and g) with formulation buffer to the
target concentration of the drug substance (Fig. 2h). If the
total error (sum of the bias and the intermediate precision)
of the IPC measurement is insufficient, then the drug sub-
stance might be too diluted or too concentrated and fails the
concentration acceptance criterion.
Figure 2. Overview of the DSP from crude harvest (a) to drug
substance (h). The IPC result (c) is used to determine the number
of purification cycles for the AEX chromatography (d and e) and
the dilution of the diafiltration product (f and g) with formula-
tion buffer to achieve the target concentration of the final drug
substance (h).
Based on the requirements in the ATP, the method to
determine the virus particle concentration in the IPC sam-
ple should have an intermediate precision of maximally 10%
RSD and a bias of 10% in order to enable a reliable determi-
nation of the number of AEX purification cycles needed and
to accurately dilute the final diafiltration product. Method re-
peatability (i.e., within-run variation), between-run variation,
intermediate precision (sum of the within-run and between-
run variation), and bias of the concentration of virus particles
were assessed in method validation (Table 1A) for both CZE
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Figure 3. Comparison of the qPCR results (log10 vp/mL) vs. CZE
results (log10 vp/mL) of six process intermediates and the final
product. The red line represents the unit line.
and qPCR. In addition, CZE results were compared to those of
qPCR obtained for the same IPC sample (clarified harvest).
The results obtained by qPCR are log-normally distributed
and therefore the precisions were calculated in log10 vp/mL
for both methods, to allow direct comparison (Table 1A and
C).
The intermediate precisions of the CZE and qPCR
method were 6.9% RSD and 15.9% RSD, respectively
(Table 1B). Based on the between run and within run vari-
ances determined in the method validations, it can be calcu-
lated (Eq. (1)) that three measurements need to be performed
by qPCR in three analytical runs to obtain a result with a
precision of 8.1% RSD. With CZE, a single measurement is
sufficient to have a precision of 6.9% RSD (Table 1B). It takes
up to 3 days to perform the three qPCR analyses needed,
which means that the production process is on-hold for
3 days awaiting the qPCR results. With CZE, the holding
time is much shorter since only a single measurement needs
to be performed. The relative bias was 2.3 and 13.9% for CZE
and qPCR, respectively. Hence, the CZE method meets the
ATP requirement for intermediate precision of 10% RSD,
when employing a testing format of one measurement in one
analytical run. CZE also meets the ATP requirement for bias
(10%). The total error (sum of the bias and the intermediate
precision) of the CZE method for a single measurement was
estimated to be 15% based on the intermediate precision
and the relative bias according to [19].
3.2 Equivalence of CZE and VP-qPCR
Figure 3 and Table 2 show the results for 131 samples of
six different process intermediates and the final product an-
alyzed by CZE and qPCR. CBLS regression [18] was used to
demonstrate equivalence between the concentration of virus
particles determined by CZE vs. qPCR. The acceptance limits
for the difference between the CZE and qPCR results were
set at [−0.2 to 0.2] log10 vp/mL, as these are considered to
demonstrate equivalence between different qPCR results, for
example, when a new calibrant is introduced. The 95% pre-
diction interval of the difference between CZE and qPCR
results was [−0.18 to 0.16] in the entire measured range and
thus within the acceptance limits ([−0.2 to 0.2] log10 vp/mL)
for all types of process intermediates and across the range
of virus particle concentrations. In other words, 95% of the
future results of CZE or qPCR will have a difference of max-
imally ±0.2 log10 vp/mL independent of the sample type or
concentration. Therefore, it can be concluded that the CZE
and qPCR methods are interchangeable in practice for the
quantification of the adenovirus concentration.
3.3 System suitability testing
The CZE method adhered to all requirements from the ATP
(time to result 4 h, intermediate precision 10%RSD, and
bias 10%) and was implemented to routinely determine the
virus particle concentration in DSP intermediates. An impor-
tant purpose of AQbD is to be well in control of the critical
method parameters of an analytical method during routine
use. The criticality assessment was revised after method vali-
dation and the equivalence study to determine if any critical
method parameter of the CZE method was not yet adequately
controlled. The capillary coating was identified as the critical
method parameter with the highest risk to impact the accu-
racy of the virus particle concentration. The capillary coating
degrades due its exposure to the sample matrix components,
such as DNA, protein and cell debris, resulting in adenovirus
adsorption to the capillary wall. The rate of degradation of
the capillary coating is variable and can therefore not be pre-
dicted. To control the capillary coating, the system suitability
test was developed with the aim to verify the method per-
formance prior to each analytical run (Fig. 4) guarantying a
precision of 5% RSD on the adenovirus peak area and a total
error (sum of the bias and intermediate precision) of 15%
on the virus particle concentration, see Fig. 4. In addition to
the SST, the calibrant is measured as a control sample after
every five test samples and at the end of each sample sequence
(1 and Fig. 4). Decrease of the adenovirus concentration of
the control sample during the sequence indicates degrada-
tion of the capillary coating and/or adenovirus adsorption. A
decrease or increase of the adenovirus concentration of 10%
is accepted. Only the test sample results before the last valid
analysis of the control sample are processed and reported.
Routine use of the CZE method (n = 525 analytical runs)
showed that the SST failure rate is about 20% (n = 105). In
one out of five runs troubleshooting and a retest of the SST are
needed before samples can be analyzed. Although 20% of the
SST runs fail, still in 99.4% of the cases the sample data was
generated on the same day. With the strict SST requirements,
we prevented that samples were analyzed unnecessarily on a
CE system that was not working properly (i.e., not adhering
to the ATP requirements). The causes of SST failure were
monitored and in 50% (n = 53) of the cases failure was due
to instrument malfunction. Other causes were; 27% (n = 28)
material defects (e.g., capillary coating), 15% (n = 16) software
issues, 4% (n = 4) unclarities in the test procedure, and 4%
(n = 4) operator errors. Continuous improvement projects
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Figure 4. System suitability
test to assure proper perfor-
mance of the CZE method dur-
ing an analytical run.
are ongoing to prevent or solve the causes and to lower the
invalid rate of the SST, e.g., by retraining of operators.
3.4 Reducing the time-to-result
The analytical target profile (ATP) describes a time-to-result
of less than 4 h. This is the total time it should take from
sampling until reporting the processed and reviewed analyt-
ical result. Prior to test sample analysis, an SST needs to be
performed, comprising ten control-sample injections with a
total analysis time of 70 min, including capillary cleaning and
conditioning, as described above (Fig. 4). Ideally in practice,
the result of the SST is already available before the test sam-
ple is received from production, to shorten the time-to-result
by about 70 min and to allow for troubleshooting in case the
SST fails, without causing delays in production. An experi-
ment was set up to demonstrate that the SST can performed
at any time during the day by testing the SST, as shown in
Fig. 4, at t = 0, t = 8, t = 24 and t = 48 h. In addition, a
control sample, typically analyzed together with the samples
upon receipt, was also analyzed at these time points and the
virus concentration obtained at each time point was com-
pared to t = 0 h. All SSTs passed the criteria independent
of the time point. The control samples, analyzed together
with the test samples, showed a maximum difference of 10%
in virus concentration between 24 h and the initial SST re-
sults at t = 0 h. Therefore, it was concluded that the SST
can be performed at the start of the day and the test samples
can be analyzed within 24 h together with the control sam-
ple (criterion: maximum difference of 10% in the adenovirus
concentration compared to the SST), see Fig. 5.
With this approach, the time-to-result for the analysis
of an IPC sample is 90 min in total: 15 min to receive the
sample, 10 min to analyze the IPC sample (Fig. 1a) and a
control sample (Fig. 1d), 15 min for data processing, 15 min
for result reporting, and 30 min for review (Fig. 5). The SST
is typically run in the morning and the IPC sample from
production can be received at any time during the day. In this
way, the process hold time is maximally 2 h (Fig. 5).
3.5 Method performance during routing
use—control charts
In addition to system suitability testing, the method perfor-
mance during routine use was controlled by monitoring for
each result–the migration time and peak area RSD% (n = 6)
of the adenovirus peak, and the concentration of the sys-
tem suitability control sample with defined control limits.
For diagnostic purposes, the following parameters were also
recorded in time for each individual CE system: capillary lot
number, number of injections per capillary, the CE current
during each analysis, the adenovirus peak width, and the re-
gression slope of the calibrant. Control charts were updated
after each method run to verify that the method performance
was consistently as expected, meeting the criteria of the sys-
tem suitability test and the requirements of the original ATP,
see Fig. 6.
So far, 18,108 samples have been analyzed in 525 analyt-
ical runs. Three out of the 525 runs were invalid (invalid rate
of 0.6%) meaning that SST passed the criteria, but the control
samples during the run did not. The test sample results in
those specific runs could not be generated or reported on the
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Figure 5. CZE approach for in-
process control testing. The
SST (70 min, ten injection) is
run prior to receipt of the pro-
cess samples. After that, the
IPC sample can be analyzed
within 24 h. Upon IPC sam-
ple receipt, the test sample
and a control sample are ana-
lyzed. The data are processed
and reported only if both the
test sample and control sam-
ple criteria are met.
Figure 6. Control charts of
(A) the adenovirus concen-
tration (vp/mL) and (B) the
adenovirus peak area RSD.
USL = upper specification
limit, LSL = lower specifica-
tion limit. The letters A, B,
and C correspond with the SD
zones. A = 3 * SD, B = 2 * SD
and C = 1 * SD.
same day. The control plot, in Fig. 6A, shows that the mean
adenovirus concentration is 0.96 × 1011 vp/mL (a relative
bias of 4%, n = 525) and 99.6% of the data points fall within
the acceptance limits of 0.85–1.15 × 1011 vp/mL. No trends
were observed and the total error of the CZE method was still
15% after 525 runs. Figure 6B shows the control plot of
the repeatability (SD) of the adenovirus peak area with con-
trol limits of 0–5% RSD. The average RSD is 1.0% over 525
runs and 100% of the analysis had a RSD% result lower than
the upper acceptance limit (5%) assuring the repeatability
requirements as defined in the ATP.
4 Concluding remarks
A CZE method was successfully implemented for quantifica-
tion of the adenovirus concentration in an IPC sample from
the DSP. Analytical-quality-by-design was used to validate and
implement the test method and was used to define a control
strategy for the critical method parameters. The CZE method
has been implemented in six different labs, eight instruments
have been installed, and 20 operators have been trained. An
extensive system suitability test and trending of critical data
from the analytical method assured that after 525 analytical
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runs, over 2 years, the precision and bias of the method still
adhered to the original requirements from the analytical tar-
get profile.
The intermediate precision of the CZE method was 7%
RSD (testing format: one measurement in one analytical run)
and the relative bias on the virus particle concentration of the
IPC was 2.3%. The current qPCR method requires a test-
ing format of three measurements in three analytical runs to
achieve an intermediate precision of 8% RSD. This means
that the production process can be on hold for up to three
days awaiting the qPCR result. As described in this paper,
the adenovirus concentrations determined by CZE and qPCR
are equivalent, as demonstrated by statistical analysis (CBLS
regression) of results for 131 representative samples. Since
statistical analysis showed that CZE and qPCR are inter-
changeable in practice for quantification of the adenovirus
concentration, and given that the IPC concentration could be
determined much faster by CZE – with a time-to-result of
less than 2 h, from sampling the clarified harvest (the IPC)
to reporting the adenovirus concentration – it is concluded
that the CZE method allows for accurate, precise, and fast de-
termination of virus particle concentration, thereby enabling
a faster determination of the number of purification cycles
of the AEX chromatography in the DSP and the accurate
dilution of diafiltration product to the final drug substance.
The authors have declared no conflict of interest.
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